Wenjing Liu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Chronic Obstructive Pulmonary Disease

Atopic Dermatitis

Signaling Pathway

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Xin Wu, Yuanhuan Yu, Meiyan Wang, Di Dai, Jianli Yin, Wenjing Liu, Deqiang Kong, Shasha Tang, Meiyao Meng, Tian Gao, Yuanjin Zhang, Yang Zhou, Ningzi Guan, Shangang Zhao, Haifeng Ye
AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation. Nature communications 15 (1) (2024)
Yuanhuan Yu, Xin Wu, Meiyan Wang, Wenjing Liu, Li Zhang, Ying Zhang, Zhilin Hu, Xuantong Zhou, Wenzheng Jiang, Qiang Zou, Fengfeng Cai, Haifeng Ye
Author Correction: Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy. Nature communications 15 (1) (2024)
Xin Wu, Yuanhuan Yu, Meiyan Wang, Di Dai, Jianli Yin, Wenjing Liu, Deqiang Kong, Shasha Tang, Meiyao Meng, Tian Gao, Yuanjin Zhang, Yang Zhou, Ningzi Guan, Shangang Zhao, Haifeng Ye
AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation. Nature communications 15 (1) (2024)
Yuanhuan Yu, Xin Wu, Meiyan Wang, Wenjing Liu, Li Zhang, Ying Zhang, Zhilin Hu, Xuantong Zhou, Wenzheng Jiang, Qiang Zou, Fengfeng Cai, Haifeng Ye
Author Correction: Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy. Nature communications 15 (1) (2024)
Xin Wu, Yuanhuan Yu, Meiyan Wang, Di Dai, Jianli Yin, Wenjing Liu, Deqiang Kong, Shasha Tang, Meiyao Meng, Tian Gao, Yuanjin Zhang, Yang Zhou, Ningzi Guan, Shangang Zhao, Haifeng Ye
AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation. Nature communications 15 (1) (2024)
Yuanhuan Yu, Xin Wu, Meiyan Wang, Wenjing Liu, Li Zhang, Ying Zhang, Zhilin Hu, Xuantong Zhou, Wenzheng Jiang, Qiang Zou, Fengfeng Cai, Haifeng Ye
Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy. Nature communications 13 (1) (2022)